Lingyu Fu
About Lingyu Fu
Lingyu Fu is a Manager of Regulatory Affairs at BeiGene in Beijing, China, with expertise in hematology and oncology products. She has a background in medical writing and regulatory submissions, having previously worked at The Janssen Pharmaceutical Companies of Johnson & Johnson.
Professional Title and Current Role
Lingyu Fu is currently working as Manager, Regulatory Affairs at BeiGene in Beijing City, China. In this role, Fu leads regulatory affairs activities for multiple oncology drugs, including Zanubrutinib, Ociperlimab, SEA-CD70, and Sylvant.
Previous Experience at Janssen Pharmaceuticals
Before joining BeiGene, Lingyu Fu worked at The Janssen Pharmaceutical Companies of Johnson & Johnson. Fu started as a Medical Writer Intern from 2014 to 2015 and was later promoted to Senior Medical Writing Scientist, a role held from 2015 to 2018. These positions were based in Beijing City, China.
Education Background
Lingyu Fu completed a Master’s degree in Social & Administrative Pharmacy at China Pharmaceutical University, studying from 2012 to 2015. Fu also holds a Bachelor’s degree in Bioengineering from the same university, obtained after studying from 2007 to 2011.
Expertise in Regulatory Affairs
Lingyu Fu has substantial expertise in regulatory affairs, specifically for hematology and oncology products. Fu's experience includes working on regulatory submissions and ensuring compliance for new drug applications in China. This background provides a comprehensive understanding of drug development and approval processes.